Ewing's sarcoma natural history: Difference between revisions
| Line 7: | Line 7: | ||
==Prognosis== | ==Prognosis== | ||
Out of all primary [[musculoskeletal]] [[tumors]], Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> | Out of all primary [[musculoskeletal]] [[tumors]], Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> In fact, prior to multi-drug [[chemotherapy]], the survival rate was less than 10%. Now that there have been many options developed, such as chemotherapy, surgery, and irradiation, long term survival has increased to greater than 50% in most clinical centers.<ref name="pmid17272319">{{cite journal |author=Iwamoto Y |title=Diagnosis and treatment of Ewing's sarcoma |journal=[[Japanese Journal of Clinical Oncology]] |volume=37 |issue=2 |pages=79–89 |year=2007 |month=February |pmid=17272319 |doi=10.1093/jjco/hyl142 |url=http://jjco.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17272319 |accessdate=2011-12-09}}</ref> | ||
Staging attempts to distinguish patients with localized from those with [[metastasis|metastatic]] disease. Most commonly, [[metastasis|metastases]] occur in the chest, bone and/or bone marrow. Less common sites include the [[central nervous system]] and [[lymph node]]s. | Staging attempts to distinguish patients with localized from those with [[metastasis|metastatic]] disease. Most commonly, [[metastasis|metastases]] occur in the chest, bone and/or bone marrow. Less common sites include the [[central nervous system]] and [[lymph node]]s. | ||
Revision as of 15:36, 9 December 2011
|
Ewing's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ewing's sarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Ewing's sarcoma natural history |
|
Risk calculators and risk factors for Ewing's sarcoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-In-Chief: Michael Maddaleni, B.S.
Overview
Natural History
Prognosis
Out of all primary musculoskeletal tumors, Ewing's Sarcoma has maintained the form with the most unfavorable long term prognosis.[1] In fact, prior to multi-drug chemotherapy, the survival rate was less than 10%. Now that there have been many options developed, such as chemotherapy, surgery, and irradiation, long term survival has increased to greater than 50% in most clinical centers.[1] Staging attempts to distinguish patients with localized from those with metastatic disease. Most commonly, metastases occur in the chest, bone and/or bone marrow. Less common sites include the central nervous system and lymph nodes.
Survival for localized disease is 65-70% when treated with chemotherapy. Long term survival for metastatic disease can be less than 10% but some sources state it is 25-30%.
Complications
References
- ↑ 1.0 1.1 Iwamoto Y (2007). "Diagnosis and treatment of Ewing's sarcoma". Japanese Journal of Clinical Oncology. 37 (2): 79–89. doi:10.1093/jjco/hyl142. PMID 17272319. Retrieved 2011-12-09. Unknown parameter
|month=ignored (help)